Menu

Bodybuilders Take Breast Cancer Drug

Tamoxifen, an endocrine therapy for women with breast cancer, is found in a supplement marketed to bodybuilders.

Feb 17, 2014
Jef Akst

Tamoxifen pillsWIKIMEDIA, NCIFor decades, some bodybuilders who’ve taken steroids to help increase their muscle mass have illegally purchased the breast cancer drug tamoxifen to prevent breast enlargement. But according to new research from Liverpool John Moores University in the U.K., others may simply have bought the dietary supplement Esto Suppress, which was found to contain the drug in three out of four samples tested by the investigators, who published their results last week (February 13) as a letter in the British Medical Journal (BMJ).

“Since the 2000s, a growing number of off-the-shelf ‘food,’ ‘herbal,’ or ‘dietary’ ‘supplements’—aimed at gym goers and people wanting to lose weight or enhance their sex lives—have contained pharmacologically active substances,” the authors wrote. “Most users will be unaware that they are taking these substances.”

The amount of tamoxifen varied by sample, with one sample containing 3.8 mg per pill. The suggested dose of Esto Suppress is two pills per day; when the drug is prescribed for early-stage breast cancer, patients typically take 20 mg a day. The researchers noted, however, that their samples were purchased two years ago, and it is not known whether the supplement still contains tamoxifen.

“This research highlights the need for consumers to be aware when choosing their sports supplements,” a spokesman for the Medicines and Healthcare Products Regulatory Agency (MHRA) told HuffPost Lifestyle. “These products may claim to increase performance but can contain powerful ingredients which can have serious side-effects.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.